On November 9, 2026, Axogen, Inc. (the “Company”) posted a corporate presentation to its website at https://ir.axogeninc.com/news-events. The Company may use the corporate presentation from time to time in conversation with analysts, investors, and others. A copy of the presentation is furnished as Exhibit 99.1.
|
Axogen, Inc. is a medical device company focused on the development and commercialization of technologies for peripheral nerve regeneration and repair. The company provides a portfolio of products for surgeons and healthcare providers to treat sensory, mixed, and motor peripheral nerve discontinuities. Key products include Avance, an acellular nerve allograft scaffold; Avance Nerve Graft, a processed human nerve allograft; Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid; Axoguard Nerve Protector and Axoguard HA+ Nerve Protector, which wrap and protect damaged nerves; Axoguard Nerve Cap, used to reduce neuroma development; and Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft. These solutions are utilized in extremities, oral maxillofacial, head and neck, breast reconstruction, and urology applications. The company serves markets in the United States, Canada, Germany, the United Kingdom, Spain, and other countries. Axogen’s products are designed to address nerve injuries resulting from traumatic events or surgical procedures, aiming to restore nerve function and improve patient quality of life. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Medical Devices | Homepage axogeninc.com |
| Sector Healthcare | IR page ir.axogeninc.com | |
|
Tags
peripheral nerve repair, nerve grafts, regenerative medicine, tissue engineering, surgical implants, neuroma prevention, nerve connectors, soft tissue matrix, Avance, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix
|
Press page ir.axogeninc.com/news-events/press-releases |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 2.504B |
| Market cap (USD) | $ 2.504B |
| P/E | -64.49 |
| PEG | — |
| P/BV | 5.05 |
| P/S | 9.38 |
| P/OCF | 88.28 |
| P/FCF | 113.60 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -13.5% |
| ROI | -8.9% |
| ROIC | -3.3% |
| Profit margin | -7.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 37.6% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 28 |
| Quality score | -41.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.208M | 187.338M | 159.012M | 138.584M | 127.358M | 112.3M | 106.712M | 83.937M | 60.426M | 41.108M | 27.331M | 16.817M | 10.947M | 7.692M | 4.849M | 3.004M | 24.911M | — | — | — | 15.929M | 14.596M |
| Net profit | -15.703M | -9.964M | -21.716M | -28.948M | -26.985M | -23.786M | -29.135M | -22.397M | -10.445M | -14.411M | -13.356M | -17.71M | -14.557M | -9.418M | -9.219M | -5.423M | 15.046M | -1.041M | -748.98K | — | 1.343M | -2.859M |
| Free cash flow | -2.933M | 1.434M | -19.588M | -36.144M | -41.216M | -31.531M | -24.536M | -24.144M | -10.343M | -12.168M | -13.461M | -10.993M | -10.624M | -8.71M | -7.1M | — | 15.44M | -476.797K | -466.947K | — | -3.295M | -1.696M |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2002 | FY 2001 | FY 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 32.73 | 16.48 | 6.83 | 9.98 | 9.37 | 17.9 | 17.89 | 20.43 | 28.3 | 9 | 5 | 3.59 | 4.49 | 2.5 | 2.4 | — | — | — | — | — | — | — |
| Price performance 12m | 0.99 | 1.41 | -0.32 | 0.07 | -0.48 | 0 | -0.12 | -0.28 | 2.14 | 0.8 | 0.39 | -0.2 | 0.8 | 0.04 | — | — | — | — | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 8.05M | 11.1M | 15.3M | 16.9M | 17.6M | 18.2M | 22.2M | 25.1M | 24.1M | 26.2M |
| ↳ YoY growth | +68.4% | +37.4% | +38.5% | +10.6% | +4.0% | +3.1% | +22.2% | +13.3% | -4.1% | +8.6% |
| ↳ 5y CAGR | +58.8% | +60.2% | +51.9% | +42.6% | +29.8% | +17.7% | +14.9% | +10.4% | +7.3% | +8.2% |
| Borrowings, current (USD) | 20,899 | 735,017 | 28,000 | 1.74M | — | — | — | — | — | — |
| Borrowings, non-current (USD) | 20.3M | 19.9M | 35,000 | 1.6M | 32M | 44.8M | 45.7M | 46.6M | 47.5M | 48.4M |
| Lease liabilities (USD) | — | — | — | 3.33M | 21.7M | 22.6M | 21.7M | 22.7M | 21.2M | 19.2M |
| Cash and deposits (USD) | 30M | 36.5M | 24.3M | 35.7M | 48.8M | 32.8M | 15.3M | 31M | 27.6M | 35.5M |
| Intangible assets (USD) | 828,979 | 936,992 | 1.18M | 1.52M | 2.05M | 2.86M | 3.65M | 4.53M | 5.58M | 6.75M |
| Right-of-use assets (USD) | — | — | — | 3.13M | 15.6M | 15.2M | 14.4M | 15.6M | 14.3M | 12.7M |
| Net debt (borrowings + leases - cash) (USD) | -9.73M | -15.9M | -24.2M | -29.1M | 5M | 34.7M | 52.1M | 38.3M | 41.1M | 32.1M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -11.2M | -9.24M | -17.9M | -19.9M | -9.63M | -13.4M | -16.1M | -5.72M | 4.54M | 812,000 |
| Purchases of property, plant and equipment (USD) | -963,787 | -1.11M | -6.28M | -4.66M | -21.9M | -27.8M | -20.1M | -13.9M | -3.1M | -3.75M |
| Purchases of intangible assets (USD) | -225,768 | -187,006 | -321,000 | -562,000 | -692,000 | -589,000 | -1.18M | -1.05M | -1.42M | -1.85M |
| Change in receivables (cash effect) (USD) | -3.35M | -3.24M | -5.11M | -2.14M | -635,000 | -499,000 | -4.64M | -2.69M | 392,000 | -2.46M |
| Change in inventories (cash effect) (USD) | -1.52M | -1.86M | -6.01M | -3.77M | -910,000 | -7.48M | -3.66M | -6.05M | -10.2M | -9.19M |
| Change in payables (cash effect) (USD) | 3.44M | 1.93M | 3.71M | 2.92M | 4.96M | -270,000 | 660,000 | 6.51M | 125,000 | -7.16M |
| Interest paid (cash effect) (USD) | -5.77M | -2.2M | -1.33M | -34,000 | -822,000 | -495,000 | 0.00 | -1.94M | -7.3M | -6.81M |
| Share-based compensation (USD) | 1.39M | 3.61M | 7.61M | 10.3M | 8.47M | 10.9M | 15.6M | 14.4M | 15.9M | 30.1M |
| Operating cash flow before change in receivables (USD) | -7.86M | -6M | -12.8M | -17.7M | -8.99M | -12.9M | -11.4M | -3.03M | 4.14M | 3.28M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -12.4M | -10.5M | -24.5M | -25.1M | -32.2M | -41.8M | -37.3M | -20.6M | 11,000 | -4.78M |
| Income detail | ||||||||||
| Research and development expense (USD) | 4.21M | 6.7M | 11.8M | 17.5M | 17.8M | 24.2M | 27.2M | 28.3M | 27.8M | 32.9M |
| ↳ 5y CAGR | +43.3% | +36.2% | +40.8% | +42.0% | +40.7% | +41.8% | +32.3% | +19.2% | +9.7% | +13.0% |
| Provision for credit losses (USD) | 79,593 | 223,323 | 852,000 | 514,000 | -105,000 | -41,000 | 612,000 | -271,000 | 650,000 | 400,000 |
| Credit cost ratio (credit losses / average receivables) (%) | 1.2% | 2.3% | 6.5% | 3.2% | 0.6% | 0.2% | 3.0% | 1.1% | 2.6% | 1.6% |
| Reported | Mar 1, 2017 | Feb 28, 2018 | Feb 26, 2019 | Feb 24, 2020 | Mar 1, 2021 | Feb 25, 2022 | Mar 14, 2023 | Mar 5, 2024 | Feb 26, 2025 | Feb 24, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
November 03, 2026 7:00am EST
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:
Canaccord Genuity 20****th Annual MedTech, Diagnostics, Digital Health & Services Forum
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Wednesday, November 11, 2026, 10:00 AM ET
Jefferies Global Healthcare Conference in London
Participation: Fireside Chat and 1x1 investor meetings
Date/Time: Fireside Chat Tuesday, November 17, 2026, 8:30 AM ET
Piper Sandler 38****th Annual Healthcare Conference
Participation: Presentation and 1x1 investor meetings
Date/Time: Presentation Wednesday, December 2, 2026, 8:00 AM ET
Webcast events can be accessed live through the Investors page at www.axogeninc.com . For those unable to listen to the live broadcast, the replay will be archived for 90 days and available on the Investors page at www.axogeninc.com .
About Axogen
Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.
Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix™, and NerveTape®.
Investors
Investors
-
News/Events
Upcoming Clinical Conferences
There are no upcoming events scheduled at this time. Sign Up for Email Alerts to receive notices about upcoming events and press releases.
Past Clinical Conferences
Sep 15, 2026
24th Annual Morgan Stanley Global Healthcare Conference
13631 Progress Blvd, Suite 400
Alachua, FL 32615
Audience
Resources
Corporate
© 2026 Axogen Corporation. All Rights Reserved. All trademarks are the property of their respective owners. See Trademark & Copyright Notice for details.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Aug 2, 2011 | Renamed | LECTEC CORP /MN/ → AXOGEN, INC. |
ETFs Holding Axogen, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| MMSC | 0.70% | 6,359 | $ 352.161K | Nov 16, 2026 |
| FTKI | 0.68% | 3,129 | $ 173.284K | Nov 16, 2026 |
| EHLS | 0.51% | 4,969 | $ 275.183K | Nov 17, 2026 |
| SAWS | 0.47% | 877 | $ 37.018K | Jul 31, 2026 |
| AFSM | 0.43% | 11,457 | $ 634.489K | Nov 16, 2026 |
| SCDS | 0.33% | 549 | $ 30.398K | Nov 17, 2026 |
| FSEG | 0.28% | 352 | $ 16.259K | Jun 30, 2026 |
| ESSC | 0.27% | 2,271 | $ 95.859K | Jul 31, 2026 |
| FESM | 0.21% | 265,129 | $ 12.246M | Jun 30, 2026 |
| SEIS | 0.18% | 22,484 | $ 1.039M | Jun 30, 2026 |
| VFMO | 0.17% | 65,187 | $ 3.309M | Aug 31, 2026 |
| PSC | 0.17% | 83,461 | $ 3.855M | Jun 30, 2026 |
| FSML | 0.11% | 3,095 | $ 142.958K | Jun 30, 2026 |
| DFAS | 0.04% | 238,970 | $ 13.239M | Nov 12, 2026 |
| MSSM | 0.02% | 3,186 | $ 161.721K | Aug 31, 2026 |
| DFSU | 0.01% | 2,496 | $ 138.278K | Nov 12, 2026 |
| DFUS | 0.00% | 15,763 | $ 873.27K | Nov 12, 2026 |
| DCOR | 0.00% | 26,374 | $ 1.461M | Nov 12, 2026 |
| DFAU | 0.00% | 7,359 | $ 407.689K | Nov 12, 2026 |
| DFAC | 0.00% | 20,221 | $ 1.12M | Nov 12, 2026 |